Related Experiment Video
Updated: Jul 18, 2026

07:30
Learning Modern Laryngeal Surgery in a Dissection Laboratory
Published on: March 18, 2020
[Supraglottic horizontal partial laryngectomies in 163 cases]
Shen-shan Jia1, Cheng Xiang, Wei-song Liu
1Department of Head and Neck Surgery, Tumor Hospital, Harbin Medical University, Harbin 150040, China. dr.jsh@163.com
Summary
Supraglottic horizontal partial laryngectomy effectively treats supraglottic laryngeal carcinoma, preserving function. Selective neck dissection is recommended for optimal outcomes in these patients.
Area of Science:
- Otolaryngology
- Surgical Oncology
- Laryngeal Cancer Research
Background:
- Supraglottic laryngeal carcinoma presents a significant challenge in head and neck oncology.
- Evaluating surgical interventions is crucial for improving patient survival and laryngeal function.
Purpose of the Study:
- To assess the clinical efficacy and functional outcomes of supraglottic horizontal partial laryngectomy.
- To determine the survival rates and recurrence patterns associated with this surgical technique.
Main Methods:
- A retrospective analysis of 163 patients with supraglottic laryngeal carcinoma treated between 1978 and 1998.
- Surgical techniques involved modified horizontal partial laryngectomy with specific reconstruction methods.
- Survival analysis utilized the Kaplan-Meier method, with stage differences tested by the Los-Rank method.
Main Results:
- Five-year survival rates varied significantly by stage (I-IV: 100% to 33.3%) and nodal status (cN0: 73.1%, cN+: 45.5%).
- The procedure demonstrated good speech and swallowing function post-operation with a 91.4% decannulation rate.
- Major causes of mortality included cervical lymph node metastasis (40%) and laryngeal recurrence (18%).
Conclusions:
- Supraglottic horizontal partial laryngectomy is highly effective for disease eradication and laryngeal function preservation when indications are carefully selected.
- Selective lateral neck dissection is advised for patients with supraglottic carcinoma to manage potential metastasis.

